Navigation Links
Lowering Risk of Breast Cancer Recurrence

A new class of drugs could reduce the risk of breast cancer recurrence in post-menopausal women. Exemestane is a third-generation aromatase inhibitor. Aromatase inhibitors are drugs that block the conversion of precursor molecules. In the case of breast cancer, aromatase inhibitors block the conversion of precursor molecules into various types of estrogenic compounds. //In a new study, coordinated through the National Surgical Adjuvant Breast and Bowel Project, researchers are studying exemestane to determine if it can further reduce the risk of breast cancer recurrence among post-menopausal women.

John Cole, M.D., from the Ochsner Clinic in New Orleans, explains the ovaries in post-menopausal women no longer make estrogen. However, estrogen is still produced from the adrenal glands and from fatty tissues. He says by using an aromatase inhibitor like exemestane, that small residual amount of estrogen is even further reduced. Dr. Cole says, "You're taking low estrogen and you're making it even lower. Now, why does that matter? Well, breast cancer cells that are hormone-sensitive can sense even those very small amounts of estrogen."

Patients are still being enrolled in the trial. Researchers across the country will enroll 3,000 postmenopausal women who have received at least five years of tamoxifen therapy. Dr. Cole says, "Tamoxifen is a different type of medication. It blocks the receptors for estrogens on cancer cells." He says previous studies show aromatase inhibitors are at least equivalent, if not superior, to tamoxifen. He says, "It seems as though lowering the estrogen levels is even more effective than blocking estrogen interaction with cells in post-menopausal patients."

Dr. Cole says, even after five years of cancer-free status, there still is an ongoing risk of breast cancer recurrence. He says about 20 percent of patients in some groups will have recurrences after five years. He tells Ivanhoe that this is the first trial of thi s kind in this setting but says the results in terms of effectiveness are years away. "It will take a while before there is enough follow-up to be able to have enough recurrences to make a statement." He is optimistic about the efficacy of exemestane and says, "Our goal is to increase the number of patients who are cured from breast cancer by preventing a recurrence. Anything that prevents recurrences is going to increase cure."
'"/>




Related medicine news :

1. Lowering blood pressure beneficial for PAD patients
2. Multi-Drug Therapy Effective in Lowering Blood Pressure
3. Multi-Drug Therapy Found To Be More Effective in Lowering B.P
4. Almonds found To Be Effective In Lowering Cholesterol
5. Almonds As Effective As Certain Drugs In Lowering Cholesterol
6. Using Cholesterol Lowering Drugs Effectively
7. Lowering cholesterol with vegetables in your diet
8. Fibre Rich Food A Boon For Lowering Cholesterol
9. Dark Chocolate Is Helpful In Lowering Blood Pressure.
10. Plant – based Foods More Effective In Lowering Cholesterol
11. Plant – based Foods More Effective In Lowering Cholestero
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement ... Vice President of North American Capital Sales at HTG Molecular . ... in the commercialization of the HTG EdgeSeq system and associated reagents in North America. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
Breaking Medicine Technology: